Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)

Speaking of SurgOnc

English - March 14, 2023 17:00 - 17 minutes - 23.9 MB - ★★★★★ - 6 ratings
Natural Sciences Science education globalcancersurgery research surgicaloncology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers

Next Episode: Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?

Rick Greene, MD, discusses with Margaret Kemeny, MD, the results of a phase III randomized trial that evaluated the effect of perioperative fluorouracil on overall survival in colon cancer. Dr. Kemeny is author of, "Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)."

Dr. Kemeny is Director of New York's Cancer Center of Excellence at Queens Cancer Center of NYC Health+Hospitals/Queens and Professor of Surgery at the Icahn School of Medicine at Mount Sinai.

http://doi.org/10.1245/S10434-022-12705-8